Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | BTK | Q06187 | 2/20 | 0.41 |
| ▸ | LPL | P06858 | 7/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.32 |
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22208077 | 1.00 | JAK2 (0.41) | JAK2BTKLPLLIPGMEN1 | |
| SCHEMBL30220350 | 0.85 | CYP1A1 (0.36) | JAK2BTKLPLLIPGCYP1A1 | |
| SCHEMBL24634354 | 0.85 | JAK2 (0.39) | JAK2BTKLPLLIPGEGFR | |
| SCHEMBL31386582 | 0.82 | JAK2 (0.37) | JAK2BTKLPLLIPGMEN1 | |
| SCHEMBL24175971 | 0.82 | JAK2 (0.37) | JAK2BTKLPLLIPGMEN1 | |
| SCHEMBL29418760 | 0.82 | LPL (0.38) | JAK2BTKLPLLIPGKDM4E | |
| SCHEMBL22208223 | 0.82 | LPL (0.38) | JAK2BTKLPLLIPGKDM4E | |
| SCHEMBL746647 | 0.81 | JAK2 (0.42) | JAK2BTKLPLLIPGALDH1A1 | |
| SCHEMBL30550009 | 0.81 | JAK2 (0.42) | JAK2BTKLPLLIPGALDH1A1 | |
| SCHEMBL30220375 | 0.81 | CYP1A1 (0.37) | JAK2BTKLPLLIPGCYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612155-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AS KRAS ONCOPROTEIN INHIBITORS | Beta Pharma, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4568952-A1 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2025-06-18 | — | — | EP | disclosed |
| EP-4526309-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2025053850-A1 | COVALENT KRAS-BINDING COMPOUNDS FOR MEDICAL TREATMENT | HYKU BIOSCIENCES INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| EP-4452416-A1 | COVALENTLY BINDING INHIBITORS OF G12S, G12D AND/OR G12E MUTANTS OF K-RAS GTPASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-10-30 | — | — | EP | disclosed |
| EP-4405337-A1 | FUSED PYRIMIDINE DERIVATIVES AS KRAS ONCOPROTEIN INHIBITORS | Beta Pharma, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| WO-2024097559-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AS KRAS ONCOPROTEIN INHIBITORS | BETA PHARMA, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024036270-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2023225302-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-4240489-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023030517-A1 | KRAS G12C INHIBITORS AND USES THEREOF | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2023-03-09 | — | — | WO | disclosed |
| WO-2023001123-A1 | NEW PYRIDOPYRIMIDINE DERIVATIVE | 上海艾力斯医药科技股份有限公司 | 2023-01-26 | — | — | WO | disclosed |
| EP-4087573-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| EP-4087843-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2022-11-16 | — | — | EP | disclosed |
| EP-4077328-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | Beta Pharma, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022187688-A1 | COVALENT KRAS-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES | UMBRA THERAPEUTICS INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022171191-A1 | COMPOUNDS AS ANTICANCER AGENTS | JINGRUI BIOPHARMA CO., LTD. (CN) | 2022-08-18 | — | — | WO | disclosed |
| CN-114835757-A | Organic electroluminescent material and device | 环球展览公司 | 2022-08-02 | — | — | CN | disclosed |
| WO-2022152233-A1 | KRAS G12C INHIBITORS | BEIGENE, LTD. (KY) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022098625-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-05-12 | — | — | WO | disclosed |